Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352035 | 0.84 | CYP3A4 (0.38) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL3314215 | 0.83 | CYP3A4 (0.45) | CYP3A4ALDH1A1 | |
| SCHEMBL3312623 | 0.81 | CYP3A4 (0.44) | CYP3A4 | |
| SCHEMBL3314903 | 0.81 | CYP3A4 (0.44) | CYP3A4ALDH1A1TSHR | |
| SCHEMBL2354243 | 0.81 | CYP3A4 (0.36) | SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4 | |
| SCHEMBL3314664 | 0.80 | CYP3A4 (0.43) | CYP3A4ALDH1A1 | |
| SCHEMBL3308471 | 0.79 | CYP3A4 (0.44) | CYP3A4ALDH1A1 | |
| SCHEMBL2354056 | 0.79 | CYP3A4 (0.42) | CYP3A4ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL2362843 | 0.79 | CYP3A4 (0.48) | CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL3308555 | 0.78 | KDM4E (0.44) | CYP3A4ALDH1A1CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232271-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-07-31 | — | — | US | claimed |
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, POLR2B | SLC6A2 4296/4885SLC6A4 4394/4885SLC6A3 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.